- 著者
- The Working Group for Renaming Diabetes Insipidus Hiroshi Arima Timothy Cheetham Mirjam Christ-Crain Deborah Cooper Mark Gurnell Juliana B Drummond Miles Levy Ann I McCormack Joseph Verbalis John Newell-Price John A H Wass
- 出版者
- The Japan Endocrine Society
- 雑誌
- Endocrine Journal (ISSN:09188959)
- 巻号頁・発行日
- vol.69, no.11, pp.1281-1284, 2022 (Released:2022-11-28)
- 参考文献数
- 10
- 被引用文献数
- 1 5
“What’s in a name? That which we call a rose/By any other name would smell as sweet.” (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and pediatric endocrine societies now proposes changing the name of “diabetes insipidus” to “Arginine Vasopressin Deficiency (AVP-D)” for central etiologies, and “Arginine Vasopressin Resistance (AVP-R)” for nephrogenic etiologies. This editorial provides both the historical context and the rational for this proposed name change.
- 著者
- Hiroshi Arima Yutaka Oiso
- 出版者
- 一般社団法人 日本内科学会
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- vol.49, no.19, pp.2043-2047, 2010 (Released:2010-10-01)
- 参考文献数
- 17
- 被引用文献数
- 4 20 8
Background and objective We previously reported that baclofen, a GABAB agonist, reduces body weight in obese mice. In this clinical study, we examined the possibility that baclofen might serve as an effective therapeutic agent for obesity in humans. Methods Seven women and three men ranging from 25-51 years of age and 31.3-41.0 kg/m2 body mass index were included in the study. Baclofen, which was started at a dose of 15 mg/day and increased to 30 mg/day in 10 days, was administered for 12 weeks. Results Administration of baclofen for 12 weeks significantly decreased both body weight (baseline: 93.30 ± 9.80 kg, 12 weeks: 91.70 ± 10.30 kg) and waist circumference (baseline: 107.9 ± 9.0 cm, 12 weeks: 105.6 ± 10.0 cm). Serum leptin levels, which possibly reflect the amount of adipose stores, were also decreased significantly by the treatment. On the other hand, there were no significant changes in the blood pressure or metabolism of glucose and lipid. No adverse effects were observed. Conclusion Although the anti-obesity effects of baclofen in the present study were mild, this pilot study suggests the possibility that baclofen might serve as a new anti-obesity drug in humans.
- 著者
- Ryotaro Bouchi Kazuo Izumi Hiroshi Ohtsu Kengo Miyo Shigeho Tanaka Noriko Satoh-Asahara Kazuo Hara Masato Odawara Yoshiki Kusunoki Hidenori Koyama Takeshi Onoue Hiroshi Arima Kazuyo Tsushita Hirotaka Watada Takashi Kadowaki Kohjiro Ueki
- 出版者
- National Center for Global Health and Medicine
- 雑誌
- GHM Open (ISSN:2436293X)
- 巻号頁・発行日
- vol.1, no.1, pp.3-11, 2021-08-29 (Released:2021-09-01)
- 参考文献数
- 30
- 被引用文献数
- 1
The use of the Internet-of-Things has improved glycemic control in individuals with diabetes in several small-scale studies with a short follow-up period. This large-scale randomized controlled trial investigates whether a smartphone-based self-management support system prevents the worsening of glycemic control in individuals with type 2 diabetes. Individuals with type 2 diabetes (age range 20-74 years; n = 2,000) will be recruited, enrolled, and randomly assigned to two groups: the intensive therapy group and the conventional therapy group. Participants in the intensive therapy group will be supervised to use an automated Internet-of-Things system that demonstrates a summary of lifelogging data (e.g., weight, blood pressure, and daily activities) obtained from each measurement device and will receive feedback messages via smartphone applications to encourage them to increase their physical activity and to monitor weight and blood pressure. Participants in the conventional therapy group are allowed to use the same measurement devices as part of the routine diabetes care but without the Internet-of-Things system. The primary endpoint is the between-group difference in HbA1c levels from baseline to 52 weeks. This randomized controlled study will test the hypothesis that an Internet-of-Things-based self-monitoring system could effectively prevent the worsening of diabetes in individuals with type 2 diabetes. The expected results of the study should facilitate the development of novel strategies for both diabetes treatment and social health.